

the haystack to identify tumour subtypes. Genomics, proteomics, methylomics (DNA methylation patterns) and metabonomics are highly information-rich technologies that have spawned the new science of bioinformatics.

How will it all look in ten years time? By then biomarkers and early surrogates for tumour response will be an absolute requirement to take a drug into man. Holistic approaches will disappear as novel, effective indicator molecules are identified. Healthy volunteers will be used for Phase I cancer studies using pharmacodynamic endpoints, and Phase II studies will be completed in months using well validated surrogates of response. For some agents with clear mechanisms of action, Phase III randomized trials could be omitted. The global regulators will have the confidence to accept a new drug based on comparisons between new and old drugs of the same class, using biological markers only. Novel methods of pharmacovigilance will pick up any disturbing trends early, setting alarm bells ringing.

The studies reviewed in the article by Nicolette and Miller will radically change cancer drug development forever. However, realigning the R&D departments of the global pharma industry to meet this brave new world is going to be a significant challenge.

Reference

- 1 Nicolette, C.A. and Miller, G.A. (2003) The identification of clinically relevant markers and therapeutic targets. *Drug Discov. Today* 8, 31–38

Karol Sikora

Global Clinical Development
AstraZeneca, Mereside, Cheshire
SK10 4TF, UK

Nuclear transport as a target for cancer therapies ▼

Currently in the literature there are at least a dozen tumor suppressor proteins and oncogene products known

to be regulated at the level of nuclear–cytoplasmic shuttling. In a recent issue of *Drug Discovery Today*, an article by Kau and Silver outlined potential anticancer strategies based on the premise of targeting the localization, and hence activity, of cancer-linked proteins, including p53 and NF- κ B, and also the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [1]. The discovery in 1994 of the first known nuclear export signal in HIV-1 Rev led to the realization that hundreds of cellular proteins actively ‘shuttle’ between the nucleus and the cytoplasm [2]. Perhaps as many as half of all known nuclear proteins can exit the nucleus. Here, I briefly address two other cancer-associated shuttling proteins, adenomatous polyposis coli (APC) protein and β -catenin, whose localization might provide future therapeutic targets.

APC is a tumor suppressor that is inactivated by the presence of truncating mutations in its encoding gene in patients with colon cancers. Many of these mutations prevent the phosphorylation and consequent proteasome-mediated degradation of β -catenin, an oncogenic transcriptional activator and a key transducing molecule of the Wnt signaling pathway. Overexpression of β -catenin is observed in numerous cancers, including colon cancer, melanoma, breast cancers and hepatocellular carcinoma [3]. Both APC and β -catenin are regulated by nuclear–cytoplasmic shuttling. APC contains five different chromosome region maintenance-1 (CRM1)-dependent nuclear export signals (NESs). By contrast, β -catenin exits the nucleus either via its association with APC or through a CRM1-independent mechanism [4]. The APC protein can shuttle in and out of the nucleus even when it is severely truncated in diseased cells. Preliminary evidence from studies in our laboratory suggests that trapping APC in the nucleus can induce tumor cell death, and thus this finding might provide a future direction for the development of anticancer agents (i.e. specific inhibitors of APC nuclear

export). Of course, as with all small-molecule inhibitor treatments, selective host cell targeting is a major consideration.

The oncogenic effects of β -catenin require its nuclear localization and transcriptional activity, both of which provide potential therapeutic targets. There has been progress in resolving the structure of complexes between β -catenin and certain key binding partners such as APC and E-cadherin, as well as T-cell factor (TCF) transcription factors, which it binds to and activates in the nucleus. Such information should assist the development of specific peptide inhibitors that prevent the cancer-linked transcription-activating function of β -catenin *in vivo* [5]. Disrupting the interaction of β -catenin with nuclear transcription factors should also indirectly stimulate the nuclear export of β -catenin and its subsequent degradation in the cytoplasm [4].

In terms of reducing nuclear accumulation of β -catenin, cadherin fragments have been used to trap β -catenin at the plasma membrane, and one could envisage several types of NES-containing peptides that exclude β -catenin from the nucleus. Further study of the transport signals and pathways that facilitate β -catenin import and export are required to fully exploit this idea.

References

- 1 Kau, T.R. and Silver, P.A. (2003) Nuclear transport as a target for cell growth. *Drug Discov. Today* 8, 78–85
- 2 Gorlich, D. (1998) Transport into and out of the cell nucleus. *EMBO J.* 17, 2721–2727
- 3 Polakis, P. (2000) Wnt signaling and cancer. *Genes Dev.* 14, 1837–1851
- 4 Henderson, B.R. and Fagotto, F. (2002) The ins and outs of APC and β -catenin nuclear transport. *EMBO Rep.* 3, 834–839
- 5 Daniels, D.L. and Weis, W.I. (2002) ICAT inhibits β -catenin binding to TCF/LEF-family transcription factors and the general coactivator p300 using independent structural modules. *Mol. Cell* 10, 573–584

Beric Henderson

Westmead Institute for Cancer Research
Westmead Millennium Institute
Darcy Road
Westmead
NSW 2145, Australia